HCPCS Level II
J2354
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
Codes near J2354
These sit next to J2354 in the CMS Level II file. All J codes
- J2327Injection, risankizumab-rzaa, intravenous, 1 mg
- J2329Injection, ublituximab-xiiy, 1mg
- J2350Injection, ocrelizumab, 1 mg
- J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
- J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
- J2355Injection, oprelvekin, 5 mg
- J2356Injection, tezepelumab-ekko, 1 mg
- J2357Injection, omalizumab, 5 mg
- J2358Injection, olanzapine, long-acting, 1 mg
- J2359Injection, olanzapine, 0.5 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00078-0180-01 | Sandostatin | Novartis Pharmaceuticals Corporation | 20 |
| 00078-0181-01 | Sandostatin | Novartis Pharmaceuticals Corporation | 40 |
| 00078-0182-01 | Sandostatin | Novartis Pharmaceuticals Corporation | 200 |
| 00641-6174-10 | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 20 |
| 00641-6175-10 | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 40 |
| 00641-6176-10 | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 200 |
| 00641-6177-01 | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 40 |
| 00641-6178-01 | Octreotide Acetate | Hikma Pharmaceuticals USA Inc. | 200 |
| 23155-0685-31 | Octreotide Acetate | Heritage Pharmaceuticals Inc. | 40 |
| 23155-0686-31 | Octreotide Acetate | Heritage Pharmaceuticals Inc. | 200 |
| 23155-0687-41 | Octreotide Acetate | Heritage Pharmaceuticals Inc. | 20 |
| 23155-0688-41 | Octreotide Acetate | Heritage Pharmaceuticals Inc. | 40 |
| 23155-0689-41 | Octreotide Acetate | Heritage Pharmaceuticals Inc. | 200 |
| 25021-0451-01 | Octreotide Acetate | Sagent Pharmaceuticals | 20 |
| 25021-0452-01 | Octreotide Acetate | Sagent Pharmaceuticals | 40 |
| 25021-0453-01 | Octreotide Acetate | Sagent Pharmaceuticals | 200 |
| 25021-0454-05 | Octreotide Acetate | Sagent Pharmaceuticals | 40 |
| 25021-0463-01 | Octreotide Acetate | Sagent Pharmaceuticals | 20 |
| 25021-0464-01 | Octreotide Acetate | Sagent Pharmaceuticals | 40 |
| 25021-0465-01 | Octreotide Acetate | Sagent Pharmaceuticals | 200 |
| 25021-0466-05 | Octreotide Acetate | Sagent Pharmaceuticals | 40 |
| 25021-0467-05 | Octreotide Acetate | Sagent Pharmaceuticals | 200 |
| 63323-0376-01 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 40 |
| 63323-0376-04 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 40 |
| 63323-0377-01 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 200 |
| 63323-0377-04 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 200 |
| 63323-0378-05 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 40 |
| 63323-0379-05 | Octreotide Acetate | FreseniUS Kabi USA, LLC | 200 |
| 67457-0239-01 | Octreotide Acetate | Mylan Institutional LLC | 20 |
| 67457-0245-01 | Octreotide Acetate | Mylan Institutional LLC | 40 |
| 67457-0246-01 | Octreotide Acetate | Mylan Institutional LLC | 200 |
| 68462-0896-10 | Octreotide Acetate | Glenmark Pharmaceuticals Inc., USA | 40 |
| 68462-0897-10 | Octreotide Acetate | Glenmark Pharmaceuticals Inc., USA | 200 |
| 71288-0566-02 | Octreotide Acetate | Meitheal Pharmaceuticals Inc. | 20 |
| 71288-0567-02 | Octreotide Acetate | Meitheal Pharmaceuticals Inc. | 40 |
| 71288-0568-02 | Octreotide Acetate | Meitheal Pharmaceuticals Inc. | 200 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.